Taking its political advocacy efforts to the next level, NASP board members and leaders visited Congress on February 24. During its inaugural “Capitol Hill Fly-In” event, NASP members met with nearly 50 congressional offices, including several key committees that are instrumental in shaping U.S. health policy.
Top NASP leaders participating in the meeting included:
Burt Zweigenhaft (NASP President), LindenCare
Rebecca Shanahan (NASP President-Elect), Avella Specialty Pharmacy
Erik Halstrom (NASP Secretary), Managed Health Care Associates, Inc.
Mike Ellis, RPh (NASP Immediate Past President), Walgreens
Mike Agostino (Board), Hy-Vee Health Solutions
Chris Ariyan, (Board), Pfizer
Thomas Blissenbach (Board), Fairview Pharmacy Services
Carmine DeNardo, (Board), ReCept Specialty Pharmacy
Mark Montgomery (Board), Axium Healthcare Pharmacy
Nuaman Tyyeb (Board) CareMed Specialty Pharmacy
Mark Vineis (Board), OncoSourceRx at Cardinal Health
Dave Walker (Board), Wal-Mart
Sheila Arquette (Co-Chair, NASP Government Affairs Committee), Independent Health
Wayne Grau, (Co-Chair, NASP Government Affairs Committee), Managed Healthcare Associates
Caleb Desrosiers, CareMed
Shara Siegle, Innovatix
Kathleen Streaker, Managed Healthcare Associates
Adrian Walker, Diplomat Specialty Pharmacy
Aaron Weise, Amber Specialty Pharmacy
While each of those participating had their own individual schedule of meetings, several group meetings were also organized with key congressional committees. Board members met with the staff Director for the Ways and Means Health Subcommittee, which has jurisdiction over legislation related to Medicare’s prescription drug benefit, as well as the Medicare hospital program. The Board also met with top staffers for the Senate Health Education Labor and Pensions (HELP) Committee, which oversees the Food and Drug Administration’s drug approval and research programs, and key aspects of the Affordable Care Act. In addition, an important meeting was held with the Senate Special Committee on Aging, which is conducting a series of hearings on pricing and competition in the prescription drug market.